Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case–Control Study of Patients with Head and Neck Squamous Cell Carcinoma
Open Access
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 11 (1) , 168-174
Abstract
No abstract availableKeywords
Funding Information
- Ride Cincinnati Foundation
- University of Cincinnati
- Center for Clinical and Translational Science, University of Cincinnati
This publication has 42 references indexed in Scilit:
- DEK Regulates Hematopoietic Stem Engraftment and Progenitor Cell ProliferationStem Cells and Development, 2011
- The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrityGenes & Development, 2011
- The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancerOncogene, 2011
- DEK in the synovium of patients with juvenile idiopathic arthritis: Characterization of DEK antibodies and posttranslational modification of the DEK autoantigenArthritis & Rheumatism, 2010
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalThe Lancet Oncology, 2010
- Melanoma Proliferation and Chemoresistance Controlled by the DEK OncogeneCancer Research, 2009
- Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation In vitro and In vivoCancer Research, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- The DEK Nuclear Autoantigen Is a Secreted Chemotactic FactorMolecular and Cellular Biology, 2006